Metastatic breast cancer: overall survival related to successive chemotherapies. What do we gain after the third line?
This retrospective study analyzed, in metastatic breast cancer (MBC), overall survival (OS) related to each subsequent line of chemotherapy (CT). We evaluated 578 patients with a MBC. Among these patients, 558 patients were stratified according to the number of different CT lines received. Median OS decreased from 22.5 to 12.3 months. Nevertheless, survival was rather stable for subsequent lines after the third line of CT around 8 months. In our study, it appeared useful to give several CT lines when possible. Subsequent lines of CT could have a beneficial effect on the survival for some patients with MBC.
Tacca
Olivier
O
Bureau de Recherche Clinique, Centre Jean Perrin, Clermont-Ferrand Cedex 1, France.
LeHeurteur
Marianne
M
Durando
Xavier
X
Mouret-Reynier
Marie-Ange
MA
Abrial
Catherine
C
Thivat
Emilie
E
Bayet-Robert
Mathilde
M
Penault-Llorca
Frederique
F
Chollet
Phillippe
P
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D011379:Prognosis; D011446:Prospective Studies; D012189:Retrospective Studies; D016879:Salvage Therapy; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome